First Tracks Biotherapeutics' drug ANB033, a CD122 antagonist, demonstrated promising Phase 1b results in treating celiac disease, showing significant improvements in tissue health and symptoms compared to Teva's IL-15 inhibitor. The drug also performed better under a tougher gluten challenge, indicating stronger efficacy. With $168 million in cash, the company is well-funded for late-stage trials and plans to expand into two more disease indications, though it may need additional financing. Key risks include the small size of the study, potential long-term immune effects, and dilution from future fundraising efforts.
First Tracks Biotherapeutics' drug ANB033 is the subject, with Pluang's health sector data providing market context. As of Oct 14, 2026 19:01 WIB, 105 of 150 health-sector US stocks rose while 40 fell. Among notable movers, ARWR gained 6.62% to USD 61.98 with a typical hold time of 5 days, contrasting with ENVB which dropped 4.29% to USD 1.34 and a longer hold time of 14 days. CLPT showed a 3.36% rise to USD 10.14, with Pluang order activity fully on the buy side and a typical hold time of 10 days.
Genesis Global won the Best AI Solution for Software Development award at the 2026 AI in Capital Markets Awards for its product Genesis Create. This software combines AI with reusable components and financial expertise to help firms develop productio...
nuVizz has been recognized as an Accelerator in the 2026 Nucleus Research Transportation Management Value Matrix for its specialized last-mile delivery technology. The platform excels in coordinating complex delivery networks involving private fleets...
ASML Holding posted a strong Q3 2026 earnings per share of $14.65, beating estimates of $12.17, driven by a 55% year-over-year sales growth and a 57.5% gross margin. Although revenue was slightly below expectations at $13.05 billion, the company bene...
Charles Schwab is set to report its Q3 2026 earnings with an estimated EPS of $1.66 and revenue around $7.18-$7.19 billion, reflecting significant growth driven by an 18.2% increase in trading revenue, net interest income, and asset management fees. ...
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
